These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 32002714)

  • 1. Pharmacophore-based designing of putative ROS-1 targeting agents for NSCLC.
    Pathak D; Choudhary S; Singh PK; Singh M; Chadha N; Silakari O
    Mol Divers; 2021 May; 25(2):1091-1102. PubMed ID: 32002714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Flavonoids as Putative ROS-1 Kinase Inhibitors Using Pharmacophore Modeling for NSCLC Therapeutics.
    Parate S; Kumar V; Hong JC; Lee KW
    Molecules; 2021 Apr; 26(8):. PubMed ID: 33917039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-guided identification of potent inhibitors of ROS1 kinase for therapeutic development against non-small cell lung cancer.
    Khan MS; Altwaijry N; Al-Bagmi MS; Alafaleq NO; Alokail MS; Shahwan M; Shamsi A
    J Biomol Struct Dyn; 2024 May; 42(8):3837-3847. PubMed ID: 37254309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural Insights into the Molecular Design of ROS1 Inhibitor for the Treatment of Non-Small Cell Lung Cancer (NSCLC).
    Adhikary R; Khandelwal R; Hussain T; Nayarisseri A; Singh SK
    Curr Comput Aided Drug Des; 2021; 17(3):387-401. PubMed ID: 32364080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of non-resistant ROS-1 inhibitors using structure based pharmacophore analysis.
    Pathak D; Chadha N; Silakari O
    J Mol Graph Model; 2016 Nov; 70():85-93. PubMed ID: 27693947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation on the binding mechanism of loratinib with the c-ros oncogene 1 (ROS1) receptor tyrosine kinase via molecular dynamics simulation and binding free energy calculations.
    Wu X; Wang Y; Wan S; Zhang J
    J Biomol Struct Dyn; 2018 Sep; 36(12):3106-3113. PubMed ID: 28893136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacophore based virtual screening, molecular docking and molecular dynamic simulation studies for finding ROS1 kinase inhibitors as potential drug molecules.
    Vanajothi R; Vedagiri H; Al-Ansari MM; Al-Humaid LA; Kumpati P
    J Biomol Struct Dyn; 2022 May; 40(8):3385-3399. PubMed ID: 33200682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolution strategy of ROS1 kinase inhibitors for use in cancer therapy.
    Liu S; Yang H; Jiang Y; Zhang T; Yan R; Zhang J
    Future Med Chem; 2018 Jul; 10(14):1705-1720. PubMed ID: 29961337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of novel benzimidazole amidines as potent multi-target inhibitors for the treatment of non-small cell lung cancer.
    Bistrović A; Krstulović L; Harej A; Grbčić P; Sedić M; Koštrun S; Pavelić SK; Bajić M; Raić-Malić S
    Eur J Med Chem; 2018 Jan; 143():1616-1634. PubMed ID: 29133046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
    Drilon A; Siena S; Dziadziuszko R; Barlesi F; Krebs MG; Shaw AT; de Braud F; Rolfo C; Ahn MJ; Wolf J; Seto T; Cho BC; Patel MR; Chiu CH; John T; Goto K; Karapetis CS; Arkenau HT; Kim SW; Ohe Y; Li YC; Chae YK; Chung CH; Otterson GA; Murakami H; Lin CC; Tan DSW; Prenen H; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Doebele RC;
    Lancet Oncol; 2020 Feb; 21(2):261-270. PubMed ID: 31838015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ALK, lung cancer, and personalized therapy: portent of the future?
    Garber K
    J Natl Cancer Inst; 2010 May; 102(10):672-5. PubMed ID: 20460631
    [No Abstract]   [Full Text] [Related]  

  • 12. Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer.
    Zhu W; Chen H; Wang Y; Wang J; Peng X; Chen X; Gao Y; Li C; He Y; Ai J; Geng M; Zheng M; Liu H
    J Med Chem; 2017 Jul; 60(14):6018-6035. PubMed ID: 28714692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ROS1 [corrected].
    Pal P; Khan Z
    J Clin Pathol; 2017 Dec; 70(12):1001-1009. PubMed ID: 28903995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
    Sgambato A; Casaluce F; Maione P; Gridelli C
    Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
    Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
    Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular docking simulation, synthesis and 3D pharmacophore studies of novel 2-substituted-5-nitro-benzimidazole derivatives as anticancer agents targeting VEGFR-2 and c-Met.
    Ibrahim HA; Awadallah FM; Refaat HM; Amin KM
    Bioorg Chem; 2018 Apr; 77():457-470. PubMed ID: 29453077
    [No Abstract]   [Full Text] [Related]  

  • 17. A new series of benzoxazole-based SIRT1 modulators for targeted therapy of non-small-cell lung cancer.
    Sever B; Akalın Çiftçi G; Altıntop MD
    Arch Pharm (Weinheim); 2021 Jan; 354(1):e2000235. PubMed ID: 32930414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, biological evaluation and molecular modeling of novel 2-amino-4-(1-phenylethoxy) pyridine derivatives as potential ROS1 inhibitors.
    Tian Y; Zhang T; Long L; Li Z; Wan S; Wang G; Yu Y; Hou J; Wu X; Zhang J
    Eur J Med Chem; 2018 Jan; 143():182-199. PubMed ID: 29174814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and biological evaluations of 2-amino-4-(1-piperidine) pyridine derivatives as novel anti crizotinib-resistant ALK/ROS1 dual inhibitors.
    Liu S; Jiang Y; Yan R; Li Z; Wan S; Zhang T; Wu X; Hou J; Zhu Z; Tian Y; Zhang J
    Eur J Med Chem; 2019 Oct; 179():358-375. PubMed ID: 31260890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer.
    Ku BM; Bae YH; Lee KY; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Invest New Drugs; 2020 Apr; 38(2):360-368. PubMed ID: 31124056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.